Thymol as adjuvant in oncology: molecular mechanisms, therapeutic potentials, and prospects for integration in cancer management

Simple item page
datacite.alternateIdentifier.citationNAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY,Vol.,2024
datacite.alternateIdentifier.doi10.1007/s00210-024-03196-3
datacite.creatorHerrera Bravo, Jesus
datacite.creatorBelen, Lisandra Herrera
datacite.creatorReyes, Maria Elena
datacite.creatorSilva, Victor
datacite.creatorFuentealba, Soledad
datacite.creatorPaz, Cristian
datacite.creatorLoren, Pia
datacite.creatorSalazar, Luis A.
datacite.creatorSharifi Rad, Javad
datacite.creatorCalina, Daniela
datacite.date2024
datacite.subject.englishAnticancer mechanisms
datacite.subject.englishApoptosis
datacite.subject.englishChemotherapy enhancement
datacite.subject.englishNatural compounds thymol
datacite.subject.englishChemotherapeutic synergism
datacite.titleThymol as adjuvant in oncology: molecular mechanisms, therapeutic potentials, and prospects for integration in cancer management
dc.date.accessioned2024-09-10T18:47:13Z
dc.date.available2024-09-10T18:47:13Z
dc.description.abstractCancer remains a global health challenge, prompting a search for effective treatments with fewer side effects. Thymol, a natural monoterpenoid phenol derived primarily from thyme (Thymus vulgaris) and other plants in the Lamiaceae family, is known for its diverse biological activities. It emerges as a promising candidate in cancer prevention and therapy. This study aims to consolidate current research on thymol's anticancer effects, elucidating its mechanisms and potential to enhance standard chemotherapy, and to identify gaps for future research. A comprehensive review was conducted using databases like PubMed/MedLine, Google Scholar, and ScienceDirect, focusing on studies from the last 6 years. All cancer types were included, assessing thymol's impact in both cell-based (in vitro) and animal (in vivo) studies. Thymol has been shown to induce programmed cell death (apoptosis), halt the cell division cycle (cell cycle arrest), and inhibit cancer spread (metastasis) through modulation of critical signaling pathways, including phosphoinositide 3-kinase (PI3K), protein kinase B (AKT), extracellular signal-regulated kinase (ERK), mechanistic target of rapamycin (mTOR), and Wnt/beta-catenin. It also enhances the efficacy of 5-fluorouracil (5-FU) in colorectal cancer treatments. Thymol's broad-spectrum anticancer activities and non-toxic profile to normal cells underscore its potential as an adjunct in cancer therapy. Further clinical trials are essential to fully understand its therapeutic benefits and integration into existing treatment protocols.
dc.identifier.urihttps://repositoriodigital.uct.cl/handle/10925/5992
dc.language.isoen
dc.publisherSPRINGER
dc.sourceNAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
oaire.resourceTypeWOS
uct.indizacionSCI
Files
Collections
MigraciĆ³n Web of Science